Prevalence of transmitted resistance to nonnucleoside reverse transcriptase inhibitors in european and north american countries over 20 years: an updated meta-analysis

HIV

Abstract

The prevalence of transmitted nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance around the world have been estimated up to 2010. Treatment recommendations have since evolved from NNRTIs to integrase strand inhibitors (INSTIs). This analysis estimates more recent trends in transmitted NNRTI resistance given emerging INSTI use. Studies reporting prevalence of transmitted NNRTI resistance in Europe, the US, and Canada were meta-analyzed to generate yearly estimates in four regions. Overall prevalence of transmitted resistance continued to rise in the US to over 10% in 2015. Prevalence in European countries with larger surveillance networks was consistent at approximately 4% from 2000 through 2012, increasing to 7% in 2016. Prevalence in European countries with fewer available data was generally lower than 5%. Two publications with Canadian data were identified, reporting 0%-3% resistance. This analysis showed increasing prevalence of transmitted NNRTI resistance up to 2016, despite the availability of newer classes of treatments.

AuthorsSJ Snedecor
JournalAIDS Research and Human Retroviruses
Therapeutic AreaInfectious Diseases
Service AreaModeling & Meta-Analysis
Year2021
LinkClick Here

Share this post